tapentadol 100 MG Oral Tablet [Nucynta]

Verify with CMS →

tapentadol

RxCUI: 854140

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.2%
Plan Coverage
10
Plans Covering
T5
Avg Tier
100%
Prior Auth Required

What the CMS Formulary Data Shows for tapentadol 100 MG Oral Tablet [Nucynta]

Per the CMS 2026 Part D formulary file, tapentadol 100 MG Oral Tablet [Nucynta] (RxNorm concept RXCUI 854140, generic name tapentadol) appears on 1 distinct formulary file spanning 10 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.

Real-world access to tapentadol 100 MG Oral Tablet [Nucynta] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 10,048 Part D beneficiaries filled tapentadol 100 MG Oral Tablet [Nucynta] in 2023, with total plan-and-beneficiary spending of $58,810,957 and an average per-beneficiary annual cost of $5,853.00. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tapentadol 100 MG Oral Tablet [Nucynta] today.

Coverage Details

Formularies covering
1
Plans covering
10
Coverage rate
0.2%
Tier range
Tier 5, Specialty
Average tier
Tier 5, Specialty

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
100% of formularies

2023 Medicare Spending

Beneficiaries
10,048
Total spending
$58,810,957
Avg per beneficiary
$5,853.00

Tier Distribution Across Plans

10 plans
Tier 5, Specialty

Standalone Drug Plans (PDP) Covering tapentadol 100 MG Oral Tablet [Nucynta]

2 standalone prescription drug plans include this drug.

Plan Insurer Tier PA ST Premium States
Blue Rx PDP Complete (PDP) HM HEALTH INSURANCE COMPANY T5 Yes No $164.80 -
Blue Rx PDP Plus (PDP) HM HEALTH INSURANCE COMPANY T5 Yes No $193.20 -

Medicare Advantage Plans (MA-PD) Covering tapentadol 100 MG Oral Tablet [Nucynta]

8 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Security Blue HMO-POS Standard (HMO-POS) HIGHMARK CHOICE COMPANY T5 Yes $51.80 PA
Freedom Blue PPO Select (PPO) HIGHMARK SENIOR HEALTH COMPANY T5 Yes $95.70 PA
Security Blue HMO-POS Deluxe (HMO-POS) HIGHMARK CHOICE COMPANY T5 Yes $95.90 PA
Freedom Blue PPO Standard (PPO) HIGHMARK SENIOR HEALTH COMPANY T5 Yes $98.20 PA
Freedom Blue PPO Select (PPO) HIGHMARK SENIOR HEALTH COMPANY T5 Yes $115.70 PA
Freedom Blue PPO Deluxe (PPO) HIGHMARK SENIOR HEALTH COMPANY T5 Yes $122.40 PA
Freedom Blue PPO Classic (PPO) HIGHMARK SENIOR HEALTH COMPANY T5 Yes $140.90 PA
Freedom Blue PPO Classic (PPO) HIGHMARK SENIOR HEALTH COMPANY T5 Yes $145.40 PA

Frequently Asked Questions

Is tapentadol 100 MG Oral Tablet [Nucynta] covered by Medicare Part D?

Yes, tapentadol 100 MG Oral Tablet [Nucynta] is covered by 10 Medicare Part D plans (0.2% of all Part D formularies).

What tier is tapentadol 100 MG Oral Tablet [Nucynta] on Medicare Part D plans?

tapentadol 100 MG Oral Tablet [Nucynta] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.

Does tapentadol 100 MG Oral Tablet [Nucynta] require prior authorization?

100% of Part D formularies require prior authorization for tapentadol 100 MG Oral Tablet [Nucynta]. Step therapy: 0%. Quantity limits: 100%.

How much does Medicare spend on tapentadol 100 MG Oral Tablet [Nucynta]?

In 2023, total Medicare Part D spending on tapentadol 100 MG Oral Tablet [Nucynta] was $58,810,957, covering 10,048 beneficiaries. The average spend per beneficiary was $5,853.00.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial